碳酸酐異構酶(carbonic anhydrase, CA)是一種金屬酶(metalloenzymes)，它在催化平衡CO2 和H2CO3扮演重要角色。關於碳酸酐異構酶和腫瘤的生成仍有爭論，尤其是關於碳酸酐異構酶在各種不同類型腫瘤的表現。本研究主要探討CAⅠ和CAⅡ的表現和口腔癌的關係。本實驗利用279個口腔鱗狀細胞癌樣本做成組織晶片，用組織免疫化學法來測試CAⅠ和CAⅡ的表現。同時用口腔癌細胞株SCC-9來確認CAⅠ及CAⅡ和細胞生長的關係。結果發現CAⅠ及CAⅡ的表現和口腔鱗狀細胞癌是否進入下一個臨床階段(p=.014 or .012)和腫瘤大小有關(p=.008 or .038)。但與淋巴結轉移、遠處轉移以及再復發無關。在細胞實驗，我們用acetazolamide當CA抑制劑，證明它會抑制SCC-9細胞生長。我們的結論是用口腔鱗狀細胞癌的樣本來分析CAⅠ和CAⅡ的表現，可以預測口腔鱗狀細胞癌局部的腫瘤生長。
Carbonic anhydrases (CA), a family of metalloenzymes, play an important role in catalyzing the equilibration of carbon dioxide (CO2) and carbonic acid (H2CO3). The role of CAs in tumorigenesis is controversial, especially regarding the expression of CA isoenzymes between various tumor types. This study explores the correlation between the expressions of CA I and CA II and the characteristic features of oral cancer. We immunohistochemically examined the expressions of CA I and CA II in 279 cases of oral squamous cell carcinoma (OSCC) using tissue microarrays. Additionally, the oral cancer cell line SCC-9 was used to confirm the relationship between CA I and CA II expression and cell growth. We found a significant correlation between positive CA I and CA II stains and OSCC for more advanced clinical stage (p = .014 or .012) and larger tumor size (p = .008 or .038), but not for positive lymph node metastasis, distal metastasis, and recurrence. In vitro analysis also showed that treatment with a CA inhibitor, acetazolamide, inhibited the growth of SCC-9 cells. We conclude that expressions of CA I and CA II in OSCC samples can be used to predict local tumor growth in OSCC patients.
